Cargando…

Gene therapy in animal models of autosomal dominant retinitis pigmentosa

Gene therapy for dominantly inherited genetic disease is more difficult than gene-based therapy for recessive disorders, which can be treated with gene supplementation. Treatment of dominant disease may require gene supplementation partnered with suppression of the expression of the mutant gene eith...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossmiller, Brian, Mao, Haoyu, Lewin, Alfred S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Vision 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3472929/
https://www.ncbi.nlm.nih.gov/pubmed/23077406
_version_ 1782246688087343104
author Rossmiller, Brian
Mao, Haoyu
Lewin, Alfred S.
author_facet Rossmiller, Brian
Mao, Haoyu
Lewin, Alfred S.
author_sort Rossmiller, Brian
collection PubMed
description Gene therapy for dominantly inherited genetic disease is more difficult than gene-based therapy for recessive disorders, which can be treated with gene supplementation. Treatment of dominant disease may require gene supplementation partnered with suppression of the expression of the mutant gene either at the DNA level, by gene repair, or at the RNA level by RNA interference or transcriptional repression. In this review, we examine some of the gene delivery approaches used to treat animal models of autosomal dominant retinitis pigmentosa, focusing on those models associated with mutations in the gene for rhodopsin. We conclude that combinatorial approaches have the greatest promise for success.
format Online
Article
Text
id pubmed-3472929
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Molecular Vision
record_format MEDLINE/PubMed
spelling pubmed-34729292012-10-17 Gene therapy in animal models of autosomal dominant retinitis pigmentosa Rossmiller, Brian Mao, Haoyu Lewin, Alfred S. Mol Vis Review Gene therapy for dominantly inherited genetic disease is more difficult than gene-based therapy for recessive disorders, which can be treated with gene supplementation. Treatment of dominant disease may require gene supplementation partnered with suppression of the expression of the mutant gene either at the DNA level, by gene repair, or at the RNA level by RNA interference or transcriptional repression. In this review, we examine some of the gene delivery approaches used to treat animal models of autosomal dominant retinitis pigmentosa, focusing on those models associated with mutations in the gene for rhodopsin. We conclude that combinatorial approaches have the greatest promise for success. Molecular Vision 2012-10-06 /pmc/articles/PMC3472929/ /pubmed/23077406 Text en Copyright © 2012 Molecular Vision. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Rossmiller, Brian
Mao, Haoyu
Lewin, Alfred S.
Gene therapy in animal models of autosomal dominant retinitis pigmentosa
title Gene therapy in animal models of autosomal dominant retinitis pigmentosa
title_full Gene therapy in animal models of autosomal dominant retinitis pigmentosa
title_fullStr Gene therapy in animal models of autosomal dominant retinitis pigmentosa
title_full_unstemmed Gene therapy in animal models of autosomal dominant retinitis pigmentosa
title_short Gene therapy in animal models of autosomal dominant retinitis pigmentosa
title_sort gene therapy in animal models of autosomal dominant retinitis pigmentosa
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3472929/
https://www.ncbi.nlm.nih.gov/pubmed/23077406
work_keys_str_mv AT rossmillerbrian genetherapyinanimalmodelsofautosomaldominantretinitispigmentosa
AT maohaoyu genetherapyinanimalmodelsofautosomaldominantretinitispigmentosa
AT lewinalfreds genetherapyinanimalmodelsofautosomaldominantretinitispigmentosa